GPP
CASC

Great Point Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Great Point Partners’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-377,900
Closed -$1.56M – 51
2017
Q1 		$1.56M Buy
+377,900
New +$1.59M 0.31% 33
2014
Q4 		– Sell
-651,325
Closed -$7.5M – 41
2014
Q3 		$7.5M Buy
651,325
+519,358
+394% +$7.93M 3.22% 15
2014
Q2 		$2.56M Sell
131,967
-33,333
-20% -$588K 1.14% 26
2014
Q1 		$2.96M Buy
+165,300
New +$2.71M 1.55% 24

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Great Point Partners's CASC Position: Q2 2017 in Review

Great Point Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 377,900 shares — an estimated $1.56M sold.

Great Point Partners first reported a position in CASC in Q1 2014 and held it in 4 quarters. The position peaked at $7.5M in Q3 2014. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • Great Point Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Great Point Partners sold 377,900 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $1.56M.
  • Great Point Partners first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Great Point Partners's Cascadian Therapeutics, Inc. position peaked at $7.5M in Q3 2014.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Great Point Partners's 13F filing for Q2 2017, filed 14 Aug 2017.